CCCC - Company ID 0001662579
The table below shows C4 Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $6.15M | $11.23M | $6.46M | $7.24M | $15.36M | $12.01M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $24.61M | $25.99M | $26.20M | $27.07M | $31.84M | $23.75M |
C4 Therapeutics, Inc. reported annual revenue of $35.95M for fiscal year 2025. That is up 1.0% from $35.58M in fiscal 2024. Over the 5 fiscal years shown, annual revenue declined from $45.78M (FY 2021) to $35.95M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $9.33M |
| $8.92M |
| $8.77M |
| $9.33M |
| $11.77M |
| $9.70M |
| Operating income | -$27.79M | -$34.41M | -$28.50M | -$29.16M | -$28.24M | -$21.44M |
| Income tax | $0.00 | $0.00 | - | $0.00 | $0.00 | $0.00 |
| Net income | -$25.13M | -$32.17M | -$26.02M | -$26.32M | -$24.67M | -$17.72M |
| EPS (diluted) | -$0.20 | -$0.44 | -$0.37 | -$0.37 | -$0.35 | -$0.26 |